Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 386

MEMORANDUM in Support re #385 MOTION to Strike Belately Disclosed Invalidity and Unenforceability Allegations and for More Time to Respond to Roche's Expert Reports filed by Amgen Inc.. (Attachments: #1 Appendix A#2 Appendix B#3 Appendix C)(Gottfried, Michael)

A

mgen Inc. v. F. Hoffmann-LaRoche LTD et al

APPENDIX C

RELIEF REQUESTED: STRIKE IDENTIFIED PORTIONS OF ROCHE'S EXPERT REPORTS

REASON MATERIAL SHOULD BE STRICKEN

Richard Flavell Expert Report, ¶¶ 13-18, 24-104, 109 Edward Harlow Expert Report, ¶¶ 122-123 Michael Fromm Expert Report, ¶¶ 17-18, 20-50, 74 James Fisher Expert Report, Entire Report Franklin Gaylis Expert Report, Entire Report Daniel Shouval Expert Report, Entire Report Rodney Kellems Expert Report, ¶¶ 71-82 John Lowe Expert Report, ¶¶ 81-94 Thomas Kadesch Expert Report, ¶¶ 27-29, 45-60 Jack Nunberg Expert Report, Entire Report Guenter Blobel Expert Report, ¶¶ 23-24 Michael Fromm Expert Report, ¶¶ 34-48, 59-64, 68 Rodney Kellems Expert Report, ¶¶ 58-59, 62-63, 94-95, 97-115 John Lowe Expert Report, ¶¶ 65-66, 70, 72, 105-127 Michael Sofocleous Expert Report, ¶¶ 293, 309, 314-316, 324 (in part), 326, 355, 373, 378-86, 387-395, 419-433

Invalidity allegation previously undisclosed in this case: Non-enablement of purification procedure and pharmaceutical composition Invalidity allegation previously undisclosed in this case: Anticipation/obviousness of patents-in-suit based on chemical synthesis of DNA Invalidity allegation previously undisclosed in this case: Anticipation/obviousness of patents-in-suit based on renal carcinoma cells, yolk sac carcinoma cells, and human fetal liver cells Invalidity allegation previously undisclosed in this case: Lack of enablement and written description for breadth of vertebrate cell claims

Patents, patent applications, and publications previously undisclosed in this case as prior art

Inequitable conduct allegations previously undisclosed in this case
Doc. 386 Att. 3

Dockets.Justia.com